# US 2020/0400696 A1 · Compounds and Methods for Use in Detecting Gabapentin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0400696 A1
- Document ID: US20200400696A1
- Status: Published application
- Kind: A1
- Application number: 17/014,678
- Filed: 2020-09-08
- Published: 2020-12-24
- Earliest claimed: 2007-02-16
- Assignees: ARK Diagnostics, Inc.
- Applicants: Ark Diagnostics, Inc.
- Inventors: Johnny Jose Valdez; Byung Sook Moon; Michael Kevin Helms; Alejandro A. Orozco
- Web page: https://patentgrep.com/patent/US20200400696A1

## CPC

- G01N 33/9473: {Anticonvulsants, e.g. phenobarbitol, phenytoin}
- C07C 229/28: the carbon skeleton being saturated and containing rings
- C07C 233/36: having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
- C07C 233/47: having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
- C07C 321/04: of an acyclic saturated carbon skeleton
- C07C 323/25: the carbon skeleton being acyclic and saturated
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor
- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/60: {characteristics by the carrier linked to the antigen}
- C07C 2601/12: with a six-membered ring
- C07C 2601/14: The ring being saturated
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Compounds and methods for use in detecting gabapentin in a sample suspected of containing gabapentin are disclosed. Gabapentin derivatives are used to produce gabapentin conjugates. A gabapentin-immunogenic carrier conjugate may be used as an immunogen for the preparation of an anti-gabapentin antibody. A gabapentin-detectable label may be used in a signal producing system in gabapentin assays.

## Claims

### Claim 1

A compound having the structure:
wherein:
R1, R2, or R3 is —X—W-L-Z,
when R1 is —X—W-L-Z, X is NH, and R2 is —OH, and R3 is —H,
when R2 is —X—W-L-Z, X is NH, R1 is —NH2, and R3 is —H, and
when R3 is —X—W-L-Z, X is a heteroatom or lower alkyl group, R1 is —NH2, and R2 is —OH;
W is a lower alkyl group or a carbonyl group;
L is a linker or at least one bond between W and Z; and
Z is a detectable label,
or a salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein said linker comprises 0 to 40 carbon atoms and 0-6 heteroatoms.

### Claim 3 (depends on 2)

The compound of claim 2, wherein W is a lower alkyl and said linker is selected from the group consisting of:
—(CH2)nC(O)—;
—C(O)(CH2)n—;
—C(O)(CH2)nNH—C(O)—;
—C(O)(CH2)mNH—C(O)(CH2)n—;
—(CH2)nSCH2C(O)—;
—(CH2)mSCH2C(O)(CH2)n—;
—(CH2)mC(O)NH(CH2)n—;
—(CH2)nNH—C(O)—;
—(CH2)mNH—C(O)(CH2)n—;
—C(O)—(CH2)n—; and
—(CH2)n—, and
wherein m, n, o, and p are independently selected from an integer from 0 to 10.

### Claim 4 (depends on 2)

The compound of claim 2, wherein W is a carbonyl and said linker is selected from the group consisting of:
—(CH2)nC(O)—;
—(CH2)nSCH2C(O)—;
—(CH2)mSCH2C(O)(CH2)n—;
—(CH2)mC(O)NH(CH2)n—;
—(CH2)nNH—C(O)—;
—(CH2)mNH—C(O)(CH2)n—; and
—(CH2)n—, and
wherein m, n, o, and p are independently selected from an integer from 0 to 10.

### Claim 5 (depends on 1)

The compound of claim 1, wherein W is a lower alkyl group and the lower alkyl group is a methyl group.

### Claim 6 (depends on 1)

The compound of claim 1, wherein said reactive functional group is selected from the group consisting of halogen, OH, SH, NH2, O-lower alkyl, epoxy, S-acyl, carboxyl, maleimidyl, haloacetamide, hydroxysuccinimidyl, succinimidyl, carbonate, anhydride and imidate.

### Claim 7 (depends on 6)

The compound of claim 6, wherein said halogen is Br or I.

### Claim 8 (depends on 1)

The compound of claim 1, having the structure:
wherein W, L, and Z are as defined in claim 1.

### Claim 9 (depends on 8)

The compound of claim 8, wherein Z is SH or Br.

### Claim 10 (depends on 8)

The compound of claim 8, wherein Z is a reactive functional group, and wherein —W-L-Z is a straight or branched alkyl chain.

### Claim 11 (depends on 8)

The compound of claim 8, wherein Z is a reactive functional group, and wherein W is a lower alkyl group.

### Claim 12 (depends on 1)

The compound of claim 1, having the structure:
wherein W, L and Z are as defined in claim 1.

### Claim 13 (depends on 12)

The compound of claim 12, wherein Z is a reactive functional group and the reactive functional group is selected from the group consisting of halogen, SH, NH2, O-lower alkyl, epoxy, S-acyl, maleimidyl, haloacetamide, hydroxysuccinimidyl, succinimidyl, carbonate, anhydride and imidate.

### Claim 14 (depends on 1)

The compound of claim 1, having the structure:
wherein W, L and Z are as defined in claim 1.

### Claim 15 (depends on 14)

The compound of claim 14, wherein Z is SH or Br.

### Claim 16 (depends on 1)

The compound of claim 1, wherein said —X—W-L-Z is selected from the group consisting of-NH—(CH2)m—SH, —NH—CO—(CH2)n—Br, and —NH—(CH2)o—S—CH2—CO—CH2—Br, and wherein m, n, and o are independently selected from 2 or 3.

### Claim at position 17

-27. (canceled)

### Claim 28 (depends on 1)

The compound of claim 1, wherein said detectable label is selected from a fluorophore, a fluorescence quencher, a radioisotope, and metal.

### Claim 29 (depends on 1)

The compound of claim 1, wherein said detectable label is selected from a polypeptide, a nucleic acid, a polysaccharide, and a lipid.

### Claim 30 (depends on 1)

A conjugate comprising the compound of claim 1 immobilized on a support.

### Claim 31 (depends on 1)

The compound of claim 1, wherein said moiety of interest is bound to the compound through CONH, NHCO, NHCONH, NH—(C=S)—NH, O—CO—NH, NH—O—CO, S, NH—(C═NH), N=N, or NH.

### Claim at position 22

-33. (canceled)

### Claim 34

A method for detecting the presence or absence of gabapentin in a sample, said method comprising:
(a) adding, to a reaction mixture, (i) a sample suspected of containing gabapentin and (ii) an anti-gabapentin antibody capable of forming of a complex of gabapentin that may be present in the sample and the antibody; and
(b) detecting the presence or absence of the complex;
wherein the presence or absence of said complex is indicative of the presence or absence of gabapentin in said sample.

### Claim 35 (depends on 34)

The method of claim 34, comprising adding a gabapentin conjugate comprising a gabapentin moiety and a detectable label to said sample, wherein the gabapentin conjugate is capable of binding to the anti-gabapentin antibody;
wherein said detecting is by detecting the detectable label.

### Claim at position 25

-40. (canceled)

### Claim 41 (depends on 34)

The method of claim 34, comprising:
measuring the amount of said conjugate bound to said anti-gabapentin antibody.

### Claim 42 (depends on 34)

The method of claim 34, wherein said detecting is quantitative.

### Claim at position 28

-44. (canceled)

### Claim 45 (depends on 35)

The method of claim 35, wherein said method is a homogeneous immunoassay.

### Claim 46 (depends on 35)

The method of claim 35, wherein said method is a heterogeneous immunoassay.

### Claim 47 (depends on 35)

The method of claim 35, wherein said sample is a biological sample obtained from a human.

### Claim 48 (depends on 47)

The method of claim 47, wherein said biological sample is blood or a blood-derived sample.

### Claim at position 33

-54. (canceled)
